Welcome to our dedicated page for Olaplex Holdings SEC filings (Ticker: OLPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Olaplex Holdings, Inc. (NASDAQ: OLPX), a science-enabled, technology-driven beauty company focused on hair health and bond-building formulations. Through these filings, investors can review how Olaplex reports on its operations, financial condition and key risks as a manufacturer in the toilet preparation and broader health and beauty space.
Olaplex’s SEC submissions include annual reports on Form 10-K, which typically contain detailed discussions of its omnichannel business model spanning professional, specialty retail and direct-to-consumer channels, as well as risk factors such as competition in the beauty industry, brand perception, international operations and indebtedness. Quarterly reports on Form 10-Q provide interim financial statements and management’s discussion of recent performance, including net sales trends and the use of non-GAAP measures like adjusted EBITDA and adjusted gross profit, as described in the company’s earnings releases.
The company also files current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly results and the stock purchase agreement through which a subsidiary acquired Purvala Bioscience, a biotech company developing bioinspired technologies for health and beauty applications, as well as board appointments. For those monitoring insider activity, Form 4 filings (when available) report changes in beneficial ownership by directors, officers and other insiders.
On Stock Titan, these documents are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain lengthy sections of 10-K and 10-Q filings, highlight key items in 8-K disclosures, and make it easier to understand topics like non-GAAP reconciliations, risk factors and significant agreements. This allows users to quickly navigate Olaplex’s regulatory history, from its bond-focused haircare strategy to corporate transactions and governance developments, without reading every page of each filing.
Baldwin Amanda reported acquisition or exercise transactions in this Form 4 filing.
Olaplex Holdings, Inc. reported that Chief Executive Officer Amanda Baldwin received a grant of 3,846,154 restricted stock units (RSUs) under the company’s 2021 Equity Incentive Plan. Each RSU represents one share of common stock and vests in four equal annual installments from March 10, 2027 through March 10, 2030, contingent on her continued employment. Following this award, she directly holds 9,581,352 shares of common stock, aligning a substantial portion of her compensation with the company’s future performance.
Olaplex Holdings, Inc. is a prestige haircare company built around patent-protected bond-building technology used by professional stylists and consumers. The brand began with in-salon treatments and an at-home product and has expanded to roughly 30 SKUs aimed at holistic hair health, addressing chemical, thermal and everyday damage.
The company sells through three interconnected channels: professional distributors and salons, specialty beauty retailers, and direct-to-consumer via Olaplex.com and third‑party e-commerce. In 2025, about 48% of net sales were in the U.S. and 52% international, with one customer representing 18% of net sales. Manufacturing is fully outsourced, with one supplier accounting for more than half of 2025 net sales and inventory purchases.
Olaplex highlights a business transformation plan, a refreshed packaging rollout, and a rebuilt innovation engine. In 2025 it launched several new products, including fine-hair shampoos and conditioners, scalp and mask treatments, and acquired Purvala Bioscience to deepen science-based innovation. The company reports over 180 issued patents worldwide and emphasizes competitive, regulatory, supply chain, brand, cybersecurity and transformation execution risks.
Olaplex Holdings reported essentially flat fiscal 2025 net sales of $422.96 million, up 0.1%, but results weakened sharply. The company swung to a GAAP net loss of $9.25 million from net income of $19.52 million, while adjusted EBITDA fell to $93.87 million from $129.67 million, with margin down to 22.2% from 30.7%.
Fourth-quarter 2025 net sales rose 4.3% to $105.12 million, driven by 18.9% growth in Professional and 6.6% in Direct-to-Consumer, partly offset by a 14.5% decline in Specialty Retail. However, Q4 GAAP net loss widened to $13.10 million.
The balance sheet showed $318.73 million of cash and cash equivalents and $352.29 million of long-term debt as of December 31, 2025, reflecting substantial debt reduction over the year. For 2026, Olaplex guides net sales between $414 million and $435 million, with adjusted gross margin of 71%–72% and adjusted EBITDA margin of 21%–22%, slightly below 2025 levels.
Olaplex Holdings, Inc. disclosed that its chief executive officer and director reported a sale of 398,560 shares of common stock on December 12, 2025. The transaction, coded as a sale, was executed at a price of $1.19 per share.
According to the filing, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units through a "sell to cover" transaction under the applicable RSU award agreement. After this transaction, the reporting person beneficially owns 5,735,198 shares of Olaplex common stock directly.
Olaplex Holdings (OLPX) reported Q3 2025 results. Net sales were $114.6 million versus $119.1 million a year ago as specialty retail and DTC softened, while professional channel sales grew. Gross margin improved to 69.1%, but higher selling, general and administrative costs—driven by a $9.3 million expense for the Purvala IPR&D asset acquisition and increased marketing and payroll—reduced operating income to $4.2 million from $28.0 million.
Net income was $11.1 million ($0.02 diluted EPS) versus $14.8 million, aided by a $9.5 million non‑cash reduction to the Tax Receivable Agreement liability related to the OBBBA. The company voluntarily repaid $300.0 million on its 2022 Term Loan Facility, lowering long‑term debt to $352.1 million and interest expense, with cash and cash equivalents at $286.4 million as of September 30, 2025.
Olaplex accrued $47.5 million for a pending settlement in the Lilien matter and recorded a $46.8 million insurance receivable. Q3 channel mix: Professional $44.5 million, Specialty retail $36.9 million, DTC $33.3 million. Shares outstanding were 667,431,776 as of September 30, 2025.
Olaplex Holdings, Inc. (OLPX) furnished an 8‑K to announce its results of operations for the third quarter ended September 30, 2025. The company disclosed that a press release with these results was issued on November 6, 2025 and is included as Exhibit 99.1.
The information under Item 2.02 is expressly stated as “furnished,” not “filed,” under the Exchange Act, and is not incorporated by reference into other filings unless specifically referenced. The filing also lists the cover page interactive data as Exhibit 104.
Olaplex Holdings, Inc. reported a material event on Form 8-K disclosing a Stock Purchase Agreement dated August 20, 2025 among Olaplex, Inc., Purvala Bioscience, Inc., the stockholders and optionholders of Purvala, and Shareholder Representative Services LLC as representative of those holders. The filing also references a press release dated August 26, 2025 and includes the cover page interactive data file embedded in the Inline XBRL document. The Form 8-K is signed on behalf of Olaplex by Amanda Baldwin, Chief Executive Officer. The filing identifies a material transaction but provides no financial terms, closing conditions, or timing details within the provided excerpt.
Tricia Glynn, a director of Olaplex Holdings, Inc. (OLPX), reported an insider acquisition on 08/13/2025. The filing shows a grant of 110,294 restricted stock units (RSUs) under the companys 2021 Equity Incentive Plan, each representing the conditional right to one share. Those RSUs vest in full on the date of Olaplexs 2026 Annual Meeting, subject to continued service. After the RSU grant, Ms. Glynn is reported to beneficially own 248,693 shares directly. The filing also discloses 499,468,771 shares held by funds and accounts managed by Advent International, L.P., where Ms. Glynn is a Managing Director; the filing includes a disclaimer limiting asserted beneficial ownership to any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 08/15/2025.
Michael James White, a director of Olaplex Holdings, Inc. (OLPX), reported an acquisition of 110,294 restricted stock units (RSUs) on 08/13/2025 at a reported price of $0.00. Each RSU represents the conditional right to one share and the RSUs will vest in full on the date of the issuer's 2026 annual meeting, subject to continued service. Following the grant, Mr. White directly beneficially owns 248,693 shares. The report also discloses that various funds and accounts managed by Advent International hold 499,468,771 shares, and Mr. White is identified as a Principal of Advent, with a disclaimer that he disclaims beneficial ownership except to the extent of any pecuniary interest.
David M. Mussaffer, a director of Olaplex Holdings, Inc. (OLPX), reported receipt of 110,294 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2021 Equity Incentive Plan. Each RSU converts to one share and will vest in full on the date of the Issuer's 2026 Annual Meeting, subject to continued service. The transaction is recorded at a $0.00 price. Following the reported award, the filing shows 248,693 shares beneficially owned directly and 499,468,771 shares held indirectly by funds/accounts managed by Advent International, L.P., where Mussaffer is Chairman and Managing Partner. The report was signed by an attorney-in-fact on 08/15/2025.